CXCL10 Specific Neutra™ Antibody Products
Product listAre you challenged by inconsistent biomarker analysis or complex inflammatory pathway targeting? Creative Biolabs' CXCL10 specific Neutra™ antibody products leverage advanced epitope mapping and validation protocols to deliver highly specific, affinity-optimized antibodies, enabling robust detection and functional neutralization of CXCL10 in preclinical and clinical studies.
Introduction to CXCL10
CXCL10 (C-X-C motif chemokine ligand 10), also known as interferon-γ-inducible protein 10 (IP-10), is a small cytokine belonging to the CXC chemokine family. It is secreted by monocytes, endothelial cells, and fibroblasts in response to interferon-γ (IFN-γ), acting as a critical chemoattractant for activated T cells and natural killer (NK) cells via binding to its receptor, CXCR3.
- Structural Insights
CXCL10 comprises 77 amino acids, including four conserved cysteine residues forming two disulfide bonds essential for its tertiary structure. The protein adopts a conserved α-helical core stabilized by hydrophobic interactions, enabling high-affinity receptor binding. The N-terminal domain of CXCL10 directly interacts with CXCR3's extracellular loops, while the C-terminal heparin-binding domain facilitates localization to inflamed tissues. Structural studies highlight its role in oligomerization, which enhances chemotactic signaling.
- Related Signaling Pathways
CXCL10-CXCR3 axis activation triggers downstream pathways such as JAK/STAT, MAPK/ERK, and PI3K/AKT, promoting leukocyte migration, Th1 polarization, and pro-inflammatory cytokine release. It amplifies IFN-γ-driven immune responses and contributes to pathological inflammation in autoimmune diseases and chronic viral infections.
Fig.1 Downstream effects of CXCL10 / CXCR3 signaling pathway.1
- CXCL10 in Disease Pathogenesis
Elevated CXCL10 levels correlate with disease severity in rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and cancer. In oncology, CXCL10 drives tumor-associated inflammation, fostering immunosuppressive microenvironments and metastatic progression. Its overexpression also links to allograft rejection and fibrosis in organ transplantation.
Applications of Anti-CXCL10 Neutralizing Antibodies
- Therapeutic Development for Autoimmune Diseases
Anti-CXCL10 antibodies suppress pathogenic Th1 responses in rheumatoid arthritis and psoriasis. Clinical trials show reduced synovial inflammation and joint damage when combined with TNF-α inhibitors.
- Oncology Immunotherapy
By disrupting CXCL10-mediated recruitment of regulatory T cells (Tregs), these antibodies enhance checkpoint inhibitor efficacy. In melanoma models, co-administration with anti-PD-1 therapies improved tumor clearance and survival rates.
- Management of Chronic Viral Infections
CXCL10 neutralization mitigates IFN-γ-driven immunopathology in hepatitis C and COVID-19. Studies report decreased viral load and lung injury in patients with hyperinflammatory syndromes.
- Prevention of Transplant Rejection
Prophylactic antibody administration reduces graft-infiltrating lymphocytes and prolongs allograft survival in renal transplant models, offering a strategy to minimize immunosuppressive drug doses.
Our Anti-CXCL10 Neutralizing Antibodies
Creative Biolabs' anti-CXCL10 antibodies are engineered to bind distinct conformational epitopes within the receptor-binding domain, effectively blocking CXCR3 interaction. Validated in ELISA, flow cytometry, and neutralization assays, these antibodies exhibit cross-reactivity with human, mouse, and primate CXCL10 isoforms. Key advantages include:
- High specificity: Minimal cross-reactivity with homologous chemokines (e.g., CXCL9/CXCL11).
- Functional neutralization: Inhibit leukocyte migration in vitro and in vivo with IC50 values <1 nM.
- Robust validation: Preclinical data demonstrate efficacy in reducing inflammation in murine models of colitis and lupus.
Creative Biolabs' CXCL10 specific Neutra™ antibody products are rigorously optimized for reproducibility across ELISA, immunohistochemistry, and functional assays. Contact our scientific team today to explore custom validation packages or request sample data.
REFERENCE
- Qiao, Xinyu, Wei Zhang, and Weijiang Zhao. "Role of CXCL10 in spinal cord injury." International Journal of Medical Sciences 19.14 (2022): 2058. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.7150/ijms.76694
